Microvast reported disappointing first-quarter results with sales falling far short of expectations, a negative adjusted EBITDA, and significant cash burn. The company's backlog dropped 14% sequentially to $168.7 million, marking a multi-year low, while the book-to-bill ratio remained below 1.0 for the fifth straight quarter. Stricter safety regulations and reduced subsidies in key Asian markets like South Korea and India are hurting sales. Due to ongoing challenges and delayed new product rollouts, the analyst downgraded Microvast's price target from $1.45 to $1.00 and reiterated a "Sell" rating, signaling bleak near-term prospects.
Willis Towers Watson, a global advisory firm, is poised for growth with a 25.3% potential stock upside, driven by new initiatives like KwantSure, a digital insurance sales channel for subcontractors, and a Geospatial Mortality Model to improve pensio...
AngioDynamics reported an 8% revenue increase to $86.6 million in Q4, driven by a 16.7% sales rise in its Med Tech division, notably from NanoKnife and AlphaVac products. H.C. Wainwright raised the price target from $16 to $19 and maintained a Buy ra...
PNC Financial Services Group reported Q2 2026 adjusted EPS of $4.85 and record revenue of $6.88 billion, surpassing analyst expectations. The growth was driven by a 15.5% rise in net interest income and a 31.4% increase in fee income, reflecting stro...
Greenlight, a leading cannabis operator, expanded its Ohio presence by opening four new dispensaries and adding in-state manufacturing, reaching the state's maximum allowed eight dispensaries. This move strengthens Greenlight's position in Ohio's lim...
Halper Sadeh LLC is investigating whether shareholders of Element Solutions Inc (ESI), Crinetics Pharmaceuticals (CRNX), and Solstice Advanced Materials (SOLS) are receiving fair treatment in their respective sale and merger transactions. The firm hi...
